RankAlpha logo
Back to Rankings

PTGX

Protagonist TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The strongest current pro-thesis evidence is primary-source based: ICOTYDE is now approved and monetizable, while the rusfertide opt-out election reduces Protagonist's U.S. launch burden and increases milestone-plus-royalty leverage if approval arrives in Q3 2026 [#PR-2026-03-18] [#PR-2026-04-28].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.1.
What can break
ICOTYDE is approved, but royalty and milestone realization still depends on Johnson & Johnson launch execution and additional indication progress.
Momentum
62
Value
56
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $107.00 · Bull $125.00 · Bear $72.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $106.54
Why
Momentum62 · Δ7d -4.1
Value56 · Δ7d +0.1
Sentiment60 · Δ7d +8.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
62
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.1
Δ21d
+5.6
Value
56
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.4
Sentiment
60
33% active weight
Current posture
7d trendImproving
Δ7d
+8.3
Δ21d
+17.2
Why this grade

Composite grade B. Momentum 62.1 / Value 56.2 / Sentiment 60.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$6.1B
Beta
2.27
Shares Out
62.52M
P/E (TTM)
133.3
P/S (TTM)
25.15
P/FCF (TTM)
82.60
Rev YoY
+0.8%
EPS YoY
-14.7%
Gross Margin
-
Op Margin
+9.1%
Net Debt
-$418.91M
Current Ratio
13.05
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology